RAPID Clinical Trial
Treating periodontal disease by targeting mTOR
What is RAPID?
RAPID is the first and only FDA-approved trial to evaluate Rapamycin in Older Adults with Periodontal Disease.
Aging is the single greatest risk factor for many diseases that affect older adults, such as cardiovascular disease, Alzheimer’s Disease, and periodontal disease. Yet, we treat such diseases individually rather than targeting the underlying process of age. The inhibition of mTOR via rapamycin has been reported to extend lifespan and healthspan in laboratory animals, and studies have shown it to improve immune response in older adults. Our goal is to harness this knowledge to target periodontal disease.
Who may participate?
Joining a research study is an important and personal choice. Thank you for considering this study.
RAPID may be an option if you are:
Over the age of 50
Think you have or have been diagnosed with periodontal disease
Have not had a cleaning in the past six (6) months.
There are other requirements for participating in the study. The study team will explain these to you.
Study Length: 12 months
Number of Visits: 10-11
What to expect
If you decide to participate, the study team will conduct a screening visit to determine if you meet the study requirements.
All participants will receive rapamycin during their time in the study, which will be given as a tablet.
You will be enrolled in the study for a minimum of 12-months. During this time, you must attend at least 10 office visits so the study team can monitor how you respond to rapamycin and the dental cleanings. You will be provided the rapamycin, exams, and all of the dental cleanings at no charge. We will also compensate you for your time.
